You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Secondary Central Nervous System Lymphoma（SCNSL）

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Primary CNS Lymphoma, Secondary CNS Lymphoma Trial in Beijing (GNC-038)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Secondary Central Nervous System Lymphoma
  • Beijing, Beijing, China
    Beijing Tiantan Hospital, Capital Medical University
Jul 31, 2022

Secondary CNS Lymphoma Trial in Beijing (Zanubrutinib, high-dose methotrexate (HD-MTX), rituximab)

Recruiting
  • Secondary Central Nervous System Lymphoma
  • Zanubrutinib, high-dose methotrexate (HD-MTX), rituximab
  • Beijing, Beijing, China
    Peking University Cancer Hospital & Institute
May 25, 2022

Primary CNS Lymphoma, Secondary CNS Lymphoma Trial (F520)

Not yet recruiting
  • Primary Central Nervous System Lymphoma
  • Secondary Central Nervous System Lymphoma
  • (no location specified)
Oct 19, 2020

PCNSL, Secondary CNS Lymphoma Trial in Beijing, Guangzhou, Shanghai (ICP-022)

Recruiting
  • PCNSL
  • Secondary Central Nervous System Lymphoma
  • Beijing, Beijing, China
  • +4 more
Jul 28, 2021

CNS Lymphoma, Secondary CNS Lymphoma Trial run by the National Cancer Institute (NCI) (TEDD-R, TEDDI-R, Ibrutinib)

Recruiting
  • Central Nervous System Lymphoma
  • Secondary Central Nervous System Lymphoma
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Primary CNS Lymphoma, Secondary CNS Lymphoma, Relapsed Cancer Trial in Miami (drug, procedure, radiation)

Not yet recruiting
  • Primary Central Nervous System Lymphoma
  • +3 more
  • Miami, Florida
    Miami Cancer Institute at Baptist Health, Inc.
Dec 23, 2022

Primary Diffuse Large B-cell Lymphoma of the CNS (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS Trial

Suspended
  • Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)
  • Aggressive B-cell Lymphoma With Secondary Involvement of the CNS
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jul 6, 2022

CNS Lymphoma, Non-Hodgkin Lymphoma Trial in Berlin

Recruiting
  • Central Nervous System Lymphoma
  • Non-Hodgkin Lymphoma
    • Berlin, Germany
      Charité - Universitätsmedizin, Med. Klinik m. S. Hämatologie, On
    Nov 8, 2021

    CNS Lymphoma Trial in Essen ([90Y]Y-PentixaTher)

    Recruiting
    • CNS Lymphoma
    • Essen, Germany
      University Hospital Essen
    Nov 16, 2023

    Relapsed or Refractory (R/R) Primary CNS Lymphoma Trial in Nanjing (thiotepa combined with pomalidomide)

    Recruiting
    • Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma
    • thiotepa combined with pomalidomide
    • Nanjing, Jiangsu, China
      Jiangsu Province People's Hospital.
    Jun 27, 2023

    CNS B-Cell Non-Hodgkin Lymphoma, Recurrent CNS Lymphoma, Refractory CNS Lymphoma Trial in Houston (Ibrutinib, Nivolumab)

    Recruiting
    • Central Nervous System B-Cell Non-Hodgkin Lymphoma
    • +2 more
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 13, 2022

    Primary CNS Lymphoma, Secondary CNS Lymphoma Trial in Saint Louis (Durvalumab, Acalabrutinib)

    Recruiting
    • Primary Central Nervous System Lymphoma
    • Secondary Central Nervous System Lymphoma
    • Saint Louis, Missouri
      Washington University School of Medicine
    Mar 14, 2022

    CNS Lymphoma, Primary CNS Lymphoma, Secondary CNS Lymphoma Trial in San Francisco (Tafasitamab, Lenalidomide)

    Recruiting
    • CNS Lymphoma
    • +2 more
    • San Francisco, California
      University of California, San Francisco
    Aug 10, 2022

    CNS Lymphoma Trial in Shanghai (Orelabrutinib, Rituximab, Chemotherapy)

    Not yet recruiting
    • CNS Lymphoma
    • Shanghai, Shanghai, China
      Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
    Jun 22, 2023

    Primary CNS Lymphoma and Primary Vitreoretinal Lymphoma Trial (intensity-modulated radiotherapy (IMRT))

    Not yet recruiting
    • Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma
    • intensity-modulated radiotherapy (IMRT)
    • (no location specified)
    Jun 4, 2023

    CNS Lymphoma Trial in Chapel Hill, Winston-Salem (Acalabrutinib, Isavuconazole)

    Recruiting
    • Central Nervous System Lymphoma
    • Chapel Hill, North Carolina
    • +1 more
    Mar 24, 2022

    Refractory CNS Lymphoma, Relapsed Primary CNS Lymphoma, Primary CNS Lymphoma Trial in Hangzhou (Nivolumab)

    Active, not recruiting
    • Refractory Central Nervous System Lymphoma
    • +2 more
    • Hangzhou, Zhejiang, China
      Jianmin Zhang
    Jul 3, 2022

    Non-hodgkin Lymphoma Trial (Methotrexate, Rituximab (where available), Ibrutinib)

    Not yet recruiting
    • Non-hodgkin Lymphoma
    • (no location specified)
    Aug 11, 2023

    Primary CNS Lymphoma Trial in Hangzhou (Rituximab, Lenalidomide, Methotrexate)

    Completed
    • Primary Central Nervous System Lymphoma
    • Hangzhou, Zhejiang, China
      2nd Affiliated Hospital, School of Medicine, Zhejiang University
    Nov 18, 2022

    Lymphoma, Lymphoma Cns Trial in Boston (Fludarabine, Cyclophosphamide, Axicabtagene Ciloleucel)

    Recruiting
    • Lymphoma
    • Lymphoma Cns
    • Boston, Massachusetts
    • +1 more
    Jan 3, 2023

    Primary CNS Lymphoma Trial in Hanzhou (Orelabrutinib, Rituximab, Methotrexate)

    Recruiting
    • Primary Central Nervous System Lymphoma
    • Hanzhou, Zhejiang, China
      2nd Affiliated Hospital, School of Medicine, Zhejiang University
    Nov 3, 2022

    Diffuse Large B Cell Lymphoma, Relapse/Recurrence, Extranodal Extension Trial in Beijing (Low-Dose Decitabine plus anti-PD-1)

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • +3 more
    • Low-Dose Decitabine plus anti-PD-1
    • Beijing, Beijing, China
      ChinaPLAGH
    Apr 18, 2023

    CNS Lymphoma Trial in China (Selinexor, Rituximab, Methotrexate)

    Not yet recruiting
    • Central Nervous System Lymphoma
    • Hefei, Anhui, China
    • +4 more
    Jan 26, 2023

    Primary CNS Lymphoma Trial in Beijing (Orelabrutinib,Rituximab and Methotrexate)

    Recruiting
    • Primary Central Nervous System Lymphoma
    • Orelabrutinib,Rituximab and Methotrexate
    • Beijing, Beijing, China
      Hospital 307
    Sep 19, 2022

    Primary CNS Lymphoma Trial in Paris (Glucarpidase, Methotrexate (MTX))

    Recruiting
    • Primary Central Nervous System Lymphoma
    • Paris, France
      Hôpital Pitié-Salpêtrière
    Oct 24, 2022